TY - JOUR
T1 - Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica
AU - Greco, Raffaella
AU - Bondanza, Attilio
AU - Vago, Luca
AU - Moiola, Lucia
AU - Rossi, Paolo
AU - Furlan, Roberto
AU - Martino, Gianvito
AU - Radaelli, Marta
AU - Martinelli, Vittorio
AU - Carbone, Maria Rosaria
AU - Lupo Stanghellini, Maria Teresa
AU - Assanelli, Andrea
AU - Bernardi, Massimo
AU - Corti, Consuelo
AU - Peccatori, Jacopo
AU - Bonini, Chiara
AU - Vezzulli, Paolo
AU - Falini, Andrea
AU - Ciceri, Fabio
AU - Comi, Giancarlo
PY - 2014
Y1 - 2014
N2 - Neuromyelitis optica is a rare neurological autoimmune disorder characterized by a poor prognosis. Immunosuppression can halt disease progression, but some patients are refractory to multiple treatments, experiencing frequent relapses with accumulating disability. Here we report on durable clinical remissions after allogeneic hematopoietic stem cell transplantation in 2 patients suffering from severe forms of the disease. Immunological data evidenced disappearance of the pathogenic antibodies and regeneration of a naive immune system of donor origin. These findings correlated with evident clinical and radiological improvement in both patients, warranting extended clinical trials to investigate this promising therapeutic option. ANN NEUROL 2014;75:447-453
AB - Neuromyelitis optica is a rare neurological autoimmune disorder characterized by a poor prognosis. Immunosuppression can halt disease progression, but some patients are refractory to multiple treatments, experiencing frequent relapses with accumulating disability. Here we report on durable clinical remissions after allogeneic hematopoietic stem cell transplantation in 2 patients suffering from severe forms of the disease. Immunological data evidenced disappearance of the pathogenic antibodies and regeneration of a naive immune system of donor origin. These findings correlated with evident clinical and radiological improvement in both patients, warranting extended clinical trials to investigate this promising therapeutic option. ANN NEUROL 2014;75:447-453
UR - http://www.scopus.com/inward/record.url?scp=84898007710&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898007710&partnerID=8YFLogxK
U2 - 10.1002/ana.24079
DO - 10.1002/ana.24079
M3 - Article
C2 - 24318127
AN - SCOPUS:84898007710
VL - 75
SP - 447
EP - 453
JO - Annals of Neurology
JF - Annals of Neurology
SN - 0364-5134
IS - 3
ER -